Gelişmiş Arama

Basit öğe kaydını göster

dc.contributor.authorKaba, Erkan
dc.contributor.authorOzyurtkan, Mehmet Oguzhan
dc.contributor.authorAyalp, Kemal
dc.contributor.authorCosgun, Tugba
dc.contributor.authorAlomari, Mazen Rasmi
dc.contributor.authorToker, Alper
dc.date.accessioned2019-08-13T12:10:23Z
dc.date.accessioned2019-08-13T15:55:58Z
dc.date.available2019-08-13T12:10:23Z
dc.date.available2019-08-13T15:55:58Z
dc.date.issued2018
dc.identifier.issn1749-8090
dc.identifier.urihttps://dx.doi.org/10.1186/s13019-018-0693-x
dc.identifier.urihttp://hdl.handle.net/11446/2181
dc.descriptionWOS: 000423094100001en_US
dc.descriptionPubMed ID: 29357877en_US
dc.description.abstractBackground: To investigate the feasibility and efficacy of salvage lung resection and describe the possible indications and contraindications in patients with primary lung cancer. Methods: Thirty patients undergoing anatomical salvage lung resection were classified into three groups: GI, patients with progressive lung tumor despite definitive chemo- and/or radiotherapy; GII, patients who underwent emergency resection; and GIII, patients in whom neoadjuvant or definitive chemo- and/or radiotherapy was contraindicated because of severe comorbidities. The groups were compared based on, peri- and postoperative factors, and survival rates. Results: The morbidity rate was 70%. Revision surgery was required in 23% of patients. Morbidity was affected by lower hematocrit and hemoglobin levels (P = 0.05). Mean hospital stay was 11 +/- 4 days, which was longer in patients in whom complications developed (P = 0.0003). The in-hospital or 30-day mortality rate was 3%. Mean relapse-free survival and overall survivals were 14 +/- 12 and 19 +/- 13 months. Conclusion: Patients with progression of the persistent primary tumor after definitive chemo- and/or radiotherapy can undergo salvage lung resection with acceptable mortality and high morbidity rates, if the tumor is considered resectable. Other indications may be considered for salvage lung resection based on each patient's specific evaluation.en_US
dc.language.isoengen_US
dc.publisherBMCen_US
dc.identifier.doi10.1186/s13019-018-0693-xen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectNon-small-cell lung canceren_US
dc.subjectSalvage surgeryen_US
dc.subjectPulmonary resectionen_US
dc.subjectSurvivalen_US
dc.titleSalvage thoracic surgery in patients with lung cancer: potential indications and benefitsen_US
dc.typearticleen_US
dc.relation.journalJOURNAL OF CARDIOTHORACIC SURGERYen_US
dc.departmentDBÜen_US
dc.identifier.volume13en_US
dc.contributor.authorID0000-0002-0793-8152en_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.department-temp[Kaba, Erkan -- Ozyurtkan, Mehmet Oguzhan -- Cosgun, Tugba] Istanbul Bilim Univ, Med Fac, Dept Thorac Surg, TR-34381 Istanbul, Turkey -- [Ayalp, Kemal -- Alomari, Mazen Rasmi -- Toker, Alper] Grp Florence Nightingale Hosp, Dept Thorac Surg, Istanbul, Turkeyen_US


Bu öğenin dosyaları:

DosyalarBoyutBiçimGöster

Bu öğe ile ilişkili dosya yok.

Bu öğe aşağıdaki koleksiyon(lar)da görünmektedir.

Basit öğe kaydını göster